Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics trade higher on medical cannabis focus

Shares have nearly tripled since the reverse takeover in late 2016.
Zelda Therapeutics trade higher on medical cannabis focus
The company has a solid pipeline of news flow in 2017

Zelda Therapeutics (ASX:ZLD) shares have continued their strong run in 2017 trading up over 85% year to date to $0.074.

This also means that the medical cannabis company’s share price has nearly tripled since listing on the Australian Stock Exchange in November, 2016 at $0.025.

Zelda is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.



Register here to be notified of future ZLD Company articles
View full ZLD profile

Zelda Therapeutics Timeline

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
shutterstock_139366595.jpg
January 25 2017
The company's update reveals a company in rude health
picture of someone with head pain
December 08 2016
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.